In 1985, Mutsuyuki Kochi reported a novel anti-tumor agent [1] after acquiring a Japanese Patent in 1969 [2]. According to his patent, 4-Hydroxybenzaldehyde is a water-soluble anti-tumor agent without any side-effects. Mostly, so called anti-tumor agents are incapable of ceasing carcinogenesis. In other words, they are only able to control multiplications of malignant tumor cells. Still in other words, they inhibit divisions of malignant cells. Therefore, they cannot be used for cancer prevention. On the contrary, 4-Hydroxybenzaldehyde can stop carcinogenesis via competitive inhibition of tyrosine kinase activity, which is regarded as a rate limiting enzyme in the pathway of carcinogenesis [3]. The concept of competitive inhibition originates in the classical enzymology, which tells you that the enzyme molecule accepts a molecule that has a similar but not identical structure of its substrate as an error. In the case of competitive inhibition of tyrosine kinase, the rate-limiting enzyme in carcinogenesis, 4-Hydroxybenzaldehyde has three groups in common with tyrosine, benzene nucleus, carbonyl group and hydroxyl group. In conclusion, 4-Hydroxybenzaldehyde can be used for cancer prevention, e.g., 1000mg of the compound dissolved in 200ml of mineral water orally taken once a month will prevent most carcinogenesis. In order to raise the probability of the prevention, you can either raise the monthly amount of the compound or shorten its interval.

A 44-year-old woman (Y. T.) visited my clinic on September 10, 2011. She told me that she had been diagnosed as an early stage of cervical cancer in April 2011, that she had received one cure-course of a chemical anti-tumor agent as an intravenous drip infusion, and that she had undergone a conical extirpation of the tumor eradicating nearby lymph-nodes. I prescribed her with 35mg/day of 4-Hydroxybenzaldehyde; 7ml of 5mg/ml aqueous solution of the drug, for 84 days. Thereafter, I prescribed her with 50mg/day of the drug for 60 days. The doses were raised to 63mg/day for 64 days, 83mg/day for 60 days, 111mg/day for 63 days, 166mg/day for 60 days, and 222mg/day for 90 days. Thereafter, I prescribed her with daily 250mg of the drug mixed with 9 times as much starch for 51 days. Thereafter, I prescribed her with daily 500mg of the drug mixed with 9 times as much starch for 90 days. Thereafter, I prescribed her with once in 5 days of 333mg of the drug as an aqueous solution (66ml of 5mg/ml solution) for 90 days. Thereafter, I prescribed her with every 5 days of 1000mg of the drug mixed with 9 times as much starch for 90 days. Thereafter, I prescribed her with every 5 days of 1500mg of the drug mixed with 9 times as much starch for 1,260 days. In order to observe possible tendency of recurrence of the tumor, blood tests of squamous cell carcinoma antigen and carcinoembryonic antigen were estimated on February 15, 2012, April 21, 2012, June 20, 2012, December 12, 2012, March 13, 2013, June 15, 2013, September 14, 2013, December 7, 2013, March 8, 2014, June 14, 2014, September 6, 2014, December 6, 2014, February 28, 2015, May 30, 2015, December 5, 2015, March 2, 2016, and June 2, 2016. Results were all within normal limits: not more than 2.0ng/ml for squamous cell carcinoma antigen and not more than 5.0ng/ml for carcinoembryonic antigen. In more detail, results of tests of squamous cell carcinoma antigen ranged from 0.5ng/ml to 1.0ng/ml and those of carcinoembryonic antigen from 0.9ng/ml to 1.8ng/ml. She claimed no subjective symptoms whatsoever. I stopped treating her on November 25, 2016. As of April 20, 2019, she was enjoying a healthy life.

1. Kochi M, Isono N, Niwayama M, Shirakabe K. Antitumor activity of benzaldehyde derivative. Cancer Treat Rep. 1985; 69: 533-37.
2. Kochi M. Manufacturing Process of Anticancer Substance. Japanese Patent. 1969.
3. Okada M, Nakagawa H. A Protein Kinase Involved in Regulation of pp60-c-src Function. J Biol Chem. 1989; 264: 20886-20893.